Rhenman & Partners Asset Management’s Halozyme HALO Stock Holding History

Rhenman & Partners Asset Management’s Portfolio HALO Stock Details HALO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-120,000	Closed	-$1.54M	–	100
2017 Q2	$1.54M	Sell	120,000 -50,000	-29%	-$668K	0.22%	81
2017 Q1	$2.2M	Sell	170,000 -10,000	-6%	-$126K	0.35%	78
2016 Q4	$1.78M	Sell	180,000 -70,000	-28%	-$767K	0.34%	78
2016 Q3	$3.02M	Hold	250,000	–	–	0.48%	69
2016 Q2	$2.16M	Sell	250,000 -181,000	-42%	-$1.79M	0.38%	73
2016 Q1	$4.08M	Buy	431,000 +21,000	+5%	+$198K	0.81%	48
2015 Q4	$7.11M	Buy	410,000 +238,000	+138%	+$3.79M	1.07%	35
2015 Q3	$2.31M	Hold	172,000	–	–	0.37%	72
2015 Q2	$3.88M	Buy	+172,000	New	+$3.02M	0.47%	73

Other funds holding HALO

Third Security Radford, Virginia $241M AUM 45.43% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

IAM

Iridian Asset Management Westport, Connecticut $247M AUM 20.65% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

SAM

Senzar Asset Management New York $34.7M AUM 0.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Rhenman & Partners Asset Management's HALO Position: Q3 2017 in Review

Rhenman & Partners Asset Management sold out of Halozyme (HALO) in Q3 2017, closing a stake of 120,000 shares — an estimated $1.54M sold.

Rhenman & Partners Asset Management first reported a position in HALO in Q2 2015 and held it in 9 quarters. The position peaked at $7.11M in Q4 2015. 166 funds tracked by Wall St. Rank hold HALO as of Q3 2017.

Rhenman & Partners Asset Management reported no remaining Halozyme position as of Q3 2017 after selling out during the quarter.
Rhenman & Partners Asset Management sold 120,000 Halozyme shares in Q3 2017, an estimated $1.54M.
Rhenman & Partners Asset Management first reported a position in Halozyme in Q2 2015 and held it in 9 quarters.
Rhenman & Partners Asset Management's Halozyme position peaked at $7.11M in Q4 2015.
166 funds tracked by Wall St. Rank held Halozyme as of Q3 2017.

Based on Rhenman & Partners Asset Management's 13F filing for Q3 2017, filed 13 Oct 2017.